Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC raised its holdings in Evolus, Inc. (NASDAQ:EOLS) by 5.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 338,254 shares of the company’s stock after purchasing an additional 18,157 shares during the quarter. Cubist Systematic Strategies LLC owned 0.54% of Evolus worth $3,670,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Perceptive Advisors LLC boosted its stake in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after buying an additional 2,477,623 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Evolus by 5,627.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after purchasing an additional 930,566 shares during the period. Lord Abbett & CO. LLC purchased a new position in shares of Evolus in the 1st quarter valued at about $11,628,000. Zimmer Partners LP acquired a new stake in shares of Evolus in the first quarter valued at about $4,200,000. Finally, BNP Paribas Financial Markets boosted its holdings in Evolus by 84.2% during the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock worth $5,683,000 after buying an additional 185,532 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Trading Down 2.4 %

Shares of EOLS opened at $15.95 on Friday. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. Evolus, Inc. has a 1-year low of $7.44 and a 1-year high of $17.70. The stock has a market cap of $998.47 million, a price-to-earnings ratio of -15.19 and a beta of 1.31. The firm has a 50 day simple moving average of $14.68 and a 200-day simple moving average of $13.18.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to the consensus estimate of $65.06 million. Equities analysts forecast that Evolus, Inc. will post -0.64 EPS for the current fiscal year.

Insider Activity at Evolus

In other news, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on EOLS. Barclays increased their target price on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.